Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrativ...( EMERYVILLE Calif. Nov. 20 /- Bionovo ...),Health

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia. The Company's oral presentation was selected as a top scoring abstract and will be presented as a part of the Best of the SIO Session on November 20, 2008.

The Phase 1B clinical trial was conducted at seven US clinical sites under the directorship of Dr. Charles Shapiro, Professor of Medicine and Director of Breast Oncology at Ohio State University. The primary objective of the study was to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company's novel, oral anticancer therapy. A total of 27 women with metastatic breast cancer were enrolled to the Phase 1B trial. To date, 48 women with advanced breast cancer have been treated with BZL101 in two early phase trials. Results from the Phase 1B trial show that BZL101 continues to be safe and well-tolerated, with early signs of clinical efficacy.

Seventeen of the twenty-seven participants in the Phase 1B clinical trial were evaluable according to the Response Evaluation Criteria in Solid Tumors (RECIST). Of these seventeen evaluable women, six were stable on study medication for greater than 90 days and three were stable on study medication for greater than 180 days. One active patient on the trial has been stable for 12 months with radiographic evidence of tumor shrinkage.

"We are eager to advance BZL101 to Phase 2 clinical testing as the drug continues to have an improved safety profile over more traditional chemotherapeutic agents, and shows encouraging clinical activity i
'/>"/>